Short Bowel Syndrome Therapeutics Market (7MM) is expected to grow from USD 2,500 million in 2025 to USD 4,100 Million in 2036, estimates DelveInsight

DelveInsight's "Short Bowel Syndrome Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Short Bowel Syndrome, historical and forecasted epidemiology as well as Short Bowel Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Short Bowel Syndrome Treatment Market Report @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Short Bowel Syndrome Market Report
• US is recognized for having one of the world's most advanced HPN programs, which plays a crucial role in supporting long-term survival for patients with chronic intestinal failure. In 2025, among the 7MM, the US had the highest number of diagnosed prevalent cases of SBS. According to DelveInsight estimates, there were 14,500 diagnosed prevalent cases of SBS in the US in 2025, which are projected to increase by 2036.
• SBS is more commonly diagnosed in women than men, with over 60% of cases occurring in females, compared to more than 30% in males in the US. Gender-specific diagnosed prevalence is expected to increase for both groups during the forecast period.
• SBS prevalence is higher in adults due to chronic conditions like Crohn's disease and mesenteric ischemia. In contrast, pediatric SBS incidence is higher because it often results from acute congenital or neonatal conditions such as necrotizing enterocolitis and intestinal malformations, which occur more frequently early in life.
• In the US, adults now represent the largest share (~85%) of diagnosed prevalent SBS cases, a shift driven by rising surgical volumes, an aging population, and improved post-surgical survival over the past two decades. Pediatric SBS survivors transitioning into adulthood further expand the chronic adult SBS population, adding to prevalence beyond new adult-onset cases.
• The leading Short Bowel Syndrome Companies such as Takeda, Ironwood Pharmaceuticals, Zealand Pharma, Hanmi Pharmaceuticals, Napo Therapeutics, and others.
• Promising Short Bowel Syndrome Therapies such as Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others.

Get a Free sample for the Short Bowel Syndrome Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short Bowel Syndrome Epidemiology
• Total Short Bowel Syndrome Diagnosed Prevalent Cases
• Short Bowel Syndrome Gender-specific Diagnosed Prevalent Cases
• Short Bowel Syndrome Age-specific Diagnosed Prevalent Cases
• Short Bowel Syndrome Etiology-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Short Bowel Syndrome epidemiology trends @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short Bowel Syndrome Approved Therapies
• GATTEX/REVESTIVE (teduglutide): Takeda (Shire Pharmaceuticals)
Teduglutide is a novel, recombinant analogue of human GLP-2, a naturally occurring protein involved in the rehabilitation of the intestinal lining. It has been developed to reduce dependence on parenteral nutrition in adult patients with SBS. Teduglutide has received ODD for the treatment of SBS from the EMA and the US FDA.

Short bowel syndrome Pipeline Analysis
• Apraglutide: Ironwood Pharmaceuticals (VectivBio)
Apraglutide is an investigational, next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including SBS-IF. In August 2025, according to the Q2 2025 corporate highlights, following discussions with the US FDA in April 2025, the company is finalizing a confirmatory apraglutide Phase III trial design for patients with SBS who are dependent on parenteral support and plans to align with the FDA in Q4 of 2025. Pending alignment with the FDA, Ironwood expects to initiate a confirmatory Phase III trial in the 1H of 2026.

• Glepaglutide (ZP1848): Zealand Pharma
Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for SBS. Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce or eliminate the need for parenteral support in people living with SBS. The US FDA has granted ODD for glepaglutide for the treatment of SBS. As per the Q2 2025 presentation in August 2025, the company had completed the Type A meeting with the US FDA, ensuring the alignment on the design of EASE-5, and anticipates the initiation of the Phase III trial (EASE-5) in H2 2025 to support resubmission in the US.

Short Bowel Syndrome Companies
Takeda, Ironwood Pharmaceuticals, Zealand Pharma, Hanmi Pharmaceuticals, Napo Therapeutics, and others.

Discover more about therapies set to grab major Short Bowel Syndrome market share @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Short bowel syndrome Market Outlook
The short bowel syndrome (SBS) market is evolving from reliance on total parenteral nutrition (TPN) the current cornerstone despite its cost, risks, and long-term burden toward advanced therapies that reduce dependence on parenteral support. Growing use of GLP-2 analogs such as GATTEX/REVESTIVE, along with emerging next-generation agents like apraglutide offering improved efficacy and convenient dosing, is driving this shift. With declining use of older growth hormone therapies and a strong focus on achieving intestinal autonomy, the SBS market is poised for significant growth, supported by innovation in biologics and ongoing pipeline advancements. SBS treatment remains limited to parenteral support and GATTEX, with parenteral support dominating as the standard of care. Currently, it drives the highest revenue given its widespread use and comparatively lower cost, underscoring the market's dependence on supportive rather than disease-modifying therapies.

Short Bowel Syndrome Market Strengths
• In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.
• Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Short Bowel Syndrome Market Opportunities
• Several organizations are actively working to provide information and increase awareness of such disorders.
• There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

Scope of the Short Bowel Syndrome Market Report
• Study Period: 2022-2036
• Coverage: 7MM
• Short Bowel Syndrome Companies: Takeda, Ironwood Pharmaceuticals, Zealand Pharma, Hanmi Pharmaceuticals, Napo Therapeutics, and others.
• Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
• Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies
• Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Short Bowel Syndrome Unmet Needs, KOL's views, Analyst's views, Short Bowel Syndrome Market Access and Reimbursement

To know more about Short Bowel Syndrome companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Short Bowel Syndrome Market Report Introduction
2. Executive Summary for Short Bowel Syndrome
3. SWOT analysis of Short Bowel Syndrome
4. Short Bowel Syndrome Patient Share (%) Overview at a Glance
5. Short Bowel Syndrome Market Overview at a Glance
6. Short Bowel Syndrome Disease Background and Overview
7. Short Bowel Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Short Bowel Syndrome
9. Short Bowel Syndrome Current Treatment and Medical Practices
10. Short Bowel Syndrome Unmet Needs
11. Short Bowel Syndrome Emerging Therapies
12. Short Bowel Syndrome Market Outlook
13. Country-Wise Short Bowel Syndrome Market Analysis (2020-2034)
14. Short Bowel Syndrome Market Access and Reimbursement of Therapies
15. Short Bowel Syndrome Market Drivers
16. Short Bowel Syndrome Market Barriers
17. Short Bowel Syndrome Appendix
18. Short Bowel Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.